Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
13 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
KA-PHARMA from Sint-Jans-Molenbeek, company number BE1005869016, closed financial year 2025 with a result of € 48,527 after tax. For that financial year KA-PHARMA recorded a gross margin of € 50,690 and equity of € 157,474. Compared with financial year 2024, the result moved from € 105,946 to € 48,527. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.
€ 157,474
▲ 45% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 48,527
▼ 54% vs 2024
Profit after tax over the fiscal year.
€ 78,133
▲ 256% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 154,474.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 1,315
▲ € 1,239 vs 2024
No payroll staff. An amount this small is usually a social contribution or pension premium for the director, booked under staff costs.
€ 691
▼ 33% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2,156
▲ 32% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,334
▼ 22% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 106,679 | € 50,690 | ▼ 52% |
| Profit after taxes | € 105,946 | € 48,527 | ▼ 54% |
| Equity | € 108,946 | € 157,474 | ▲ 45% |
| Total debts | € 8,512 | € 7,490 | ▼ 12% |
| Cash | € 21,976 | € 78,133 | ▲ 256% |
| Retained profit | € 105,946 | € 154,474 | ▲ 46% |
| Balance sheet total | € 117,458 | € 164,964 | ▲ 40% |
Key figures of KA-PHARMA, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to KA-PHARMA?
What happened at KA-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 48,527 (▼ 54% vs 2024). Source: NBB ↗
- New establishment in Sint-Jans-Molenbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 105,946 profit in 2024 to € 48,527 profit in 2025.
Best year ever: 2024, with € 105,946 profit.
A new publication or filing at KA-PHARMA? We notify you, reason included.
Follow KA-PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind KA-PHARMA is Aurore-Espérance Kaneza.
Directors
According to the 2025 annual accounts
Aurore-Espérance Kaneza
Director
Establishments
Establishment units
Physical locations of this company
Joseph Baecklaan 74 box 26
1080 Sint-Jans-Molenbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 13 companies are registered at this address.
All companies at this address →Urro
€ 231,102 gross margin · 2025
SWIFT LINE
€ 148,258 gross margin · 2025
A.L.S. Management
€ 25,096 gross margin · 2024
CANDARO INVEST
€ 106,343 revenue · 2022
SERVICES ONLINE
+8 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1005.869.016
- VAT number
- BE 1005.869.016
- Registered office
- Joseph Baecklaan 74 bus 26, 1080 Sint-Jans-Molenbeek
- Names & denominations
- KA-PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 February 2024
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Overige zakelijke dienstverlening, neg